Join us today, April 3, 6:30 pm Paris / 12:30 pm Eastern, for a webcast discussing topline results from REVERSE.
Consult our press release for details.
Our products and pipeline
News & Media
GenSight Biologics reports €49 million cash position as of March 31, 2018 and provides update on GS010
GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON)
GenSight Biologics Reports Full Year 2017 Financial Results